New Investment Opportunity: DayTwo
Precision nutrition to manage type 2 diabetes and other chronic diseases
"We saw our medication usage decrease by 30%"
— Regional President, CEO, major US healthcare provider
- Leveraging microbiome database containing tens of thousands of deep sequencing samples with AI to create personalized, precision nutrition to help manage type 2 diabetes and other chronic diseases, improve outcomes, save healthcare costs
- Partnerships with Fortune 1000 companies, major health insurers, pharma companies, food companies; pipeline of 163 more prospects
- Peer-reviewed research published over seven years with Mayo Clinic, Weizmann Institute in Nature, Cell and leading journals
- Projecting 140% YOY US revenue increase in 2022, 440% YOY increase in 2023
- Experienced team led by newly appointed CEO Dave Henderson, ex-MVP Healthcare, Cigna, co-founder of Oscar Health
- Featured on ABC's Good Morning America, New York Times; winner of Roche's 2020 Diabetic Care Innovation Contest
- Targeting $20M Series A with participation of most existing investors
-Dec-01-2022-05-18-33-7934-PM.png?width=840&height=452&upscale=true&name=Untitled%20design%20(1)-Dec-01-2022-05-18-33-7934-PM.png)
Watch DayTwo featured on ABC's Good Morning America
BOOK A CALL
with your Investor Relations representative
Dear Josb,
Diabetes is sweeping through America, affecting more than 37 million US citizens and costing more than $237B in direct healthcare and over $90B in reduced productivity. DayTwo is the first and only science-based company which uses microbiomes to inform clients how to eat more healthily and improve their lifestyle, and has achieved impressive initial results with more than 1,400 members.
DayTwo is now expanding to the US, creating partnerships with major corporations and healthcare providers in a B2B2C model that helps their members manage type 2 diabetes and other chronic diseases, cutting healthcare costs and increasing productivity. OurCrowd is investing in DayTwo. The details in this email are based on information received from, and verified solely by, the company.
The Problem
The effects of diabetes, both in terms of the cost of treatment and the effect on the quality of life, are enormous. In the US, the financial costs are largely paid by employers who insure over 49% of the population. American businesses are urgently searching for methods to combat diabetes and help stop the unhealthy lifestyle choices made by their employees which exacerbates the problems. Insurers are eager to cut the huge and rapidly rising costs of healthcare.
The Solution
DayTwo uses microbiome sequencing and extensive analysis of a member's microbiome to better understand how each individual responds to various types of foods. It then uses this data to advise the client on how to change the meal in order to avoid or reduce sugar spikes. DayTwo's service includes microbiome sequencing, DayTwo's user-friendly app, and provides customers with personalized, professional advice and support from a dietitian.
DayTwo has amassed the world's largest library of deep microbiomic samples and data. DayTwo's app leverages this huge trove of data using proprietary AI algorithms to provide a targeted, personalized nutrition program for each user. Its science is based on more than seven years of research at the Weizmann Institute, Mayo Clinic and other leading research centers, and has been published in leading peer-reviewed journals including Nature, Cell, and the American Journal of Clinical Nutrition.
The Traction
The company pivoted in 2022 away from its base in Israel to address the US market with a sustainable B2B2C business model that contracts with major employers and healthcare providers, enabling them to reduce costs and increase employee health and productivity.
Based on bookings achieved by the end of Q3 2022, it forecasts 140% YOY US revenue increase in 2022, and a further 440% YOY increase in 2023.
DayTwo has established partnerships with Fortune 1000 companies, major health insurers, and pharma and food companies. In addition, it has a pipeline of 163 additional prospects.
A survey of users showed significant reduction in weight, stress and hunger, with notable increases in energy and quality of sleep.
"We were delighted, absolutely, at the results for the impact on our members," said the Regional President and CEO of one major US healthcare provider. "We saw our medication usage decrease by 30%, so patients that were on medication no longer required it or had significant decreases."
DayTwo was featured on ABC's Good Morning America and the New York Times, and won Roche's 2020 Diabetic Care Innovation Contest.
The Team
Dave Henderson, appointed as CEO in July 2021, has 35 years of healthcare experience. He was VP of S&M at healthcare giant Cigna (NYSE: CI) and Chief Marketing Officer at MVP Health Care (ASX: MVP). In 2012, Dave founded and was Head of Insurance at Oscar Health (NYSE: OSCR), a firm focused on utilizing technology, design, and data to humanize healthcare. During Dave's tenure, Oscar was worth over $3B. He was also founding CEO of Kaden Health. He leads an experienced team of healthcare technologists, scientific researchers and industry experts.
The Round
OurCrowd has a $5M allocation in this time sensitive up to $20M Series A round in which most existing investors, including Marius Nacht, are participating. The company currently has runway, including internals' investment, until August 2023. The proceeds will be used to finance the company's expansion in the US, giving it sufficient runway ahead of an expected Series B financing round at the end of 2023.
Meet the CEO
We're hosting a webinar/conference call on Monday, December 5th, at 6PM Israel / 11AM New York / 8AM San Francisco for investors to meet CEO Dave Henderson to learn more about DayTwo.
Can't make the webinar? Register and we will send you a recording of the call.
The DayTwo Solution
DayTwo uses microbiome sequencing and extensive analysis of a client's microbiomic make up to better understand how each individual responds to certain types of foods, enabling them to advise the client on how and what to eat in order to avoid or reduce sugar spikes. DayTwo's service includes microbiome sequencing, the ability to use the app and professional, personalized nutritionist support, guiding the customer along the way to a healthier life.
Next steps:
0 Comments